NASDAQ:IVA Inventiva (IVA) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free IVA Stock Alerts $3.28 -0.01 (-0.30%) (As of 01:15 PM ET) Add Compare Share Share Today's Range$3.05▼$3.3050-Day Range$3.22▼$4.3652-Week Range$2.22▼$5.05Volume10,450 shsAverage Volume35,196 shsMarket Capitalization$172.13 millionP/E RatioN/ADividend YieldN/APrice Target$17.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Inventiva alerts: Email Address Inventiva MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside415.2% Upside$17.00 Price TargetShort InterestHealthy0.11% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.67Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.23) to ($2.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.67 out of 5 starsMedical Sector429th out of 909 stocksPharmaceutical Preparations Industry193rd out of 423 stocks 3.5 Analyst's Opinion Consensus RatingInventiva has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageInventiva has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.11% of the outstanding shares of Inventiva have been sold short.Short Interest Ratio / Days to CoverInventiva has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Inventiva has recently decreased by 52.75%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldInventiva does not currently pay a dividend.Dividend GrowthInventiva does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IVA. Previous Next 2.6 News and Social Media Coverage News SentimentInventiva has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Inventiva this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for IVA on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows5 people have added Inventiva to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inventiva insiders have not sold or bought any company stock.Percentage Held by Insiders32.00% of the stock of Inventiva is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 19.06% of the stock of Inventiva is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Inventiva are expected to decrease in the coming year, from ($2.23) to ($2.40) per share. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024 About Inventiva Stock (NASDAQ:IVA)Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.Read More IVA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IVA Stock News HeadlinesApril 19, 2024 | msn.comHepion ends Phase 2 study for NASH drug due to cash restraintsApril 19, 2024 | americanbankingnews.comInventiva S.A. (NASDAQ:IVA) Receives Consensus Rating of "Buy" from AnalystsApril 24, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinApril 3, 2024 | globenewswire.comInventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-FApril 1, 2024 | msn.comJulianne Moore y Nicholas Galitzine buscan seducir a un rey en “Mary & George”April 1, 2024 | markets.businessinsider.comBuy Rating Affirmed: Inventiva’s Progress and Promise in Lanifibranor’s Clinical TrialsApril 1, 2024 | finance.yahoo.comInventiva S.A. (NASDAQ:IVA) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Inventiva (IVA), Palisade Bio (PALI)April 24, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinMarch 28, 2024 | finanznachrichten.deINVENTIVA: Inventiva announces the nomination of Andre Turenne as DirectorMarch 28, 2024 | globenewswire.comInventiva announces the nomination of Andre Turenne as DirectorMarch 27, 2024 | finanznachrichten.deINVENTIVA: Inventiva reports its 2023 full-year resultsMarch 27, 2024 | globenewswire.comInventiva reports its 2023 full-year resultsMarch 22, 2024 | globenewswire.comInventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial ResultsMarch 21, 2024 | markets.businessinsider.comPromising Phase 2 Results Bolster Buy Rating for Inventiva’s Lanifibranor in Type 2 Diabetes and MASH TreatmentMarch 18, 2024 | markets.businessinsider.comPRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA ApprovalMarch 18, 2024 | globenewswire.comInventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2DMarch 18, 2024 | seekingalpha.comMadrigal: Accelerated Rezdiffra Approval Puts It In The NASH LeadMarch 14, 2024 | bizjournals.comShares of Madrigal Pharmaceuticals soar on FDA approval for NASH treatmentMarch 13, 2024 | globenewswire.comInventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2DMarch 8, 2024 | markets.businessinsider.comInventiva’s Clinical Progress and Financial Valuation Reinforce Buy RatingMarch 8, 2024 | markets.businessinsider.comInventiva’s Buy Rating Affirmed: Swift Management Actions and Strong Safety Profile Signal Promising OutlookMarch 7, 2024 | globenewswire.comInventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumedFebruary 17, 2024 | markets.businessinsider.comBuy Rating for Inventiva Despite Temporary Trial Setback: Analyst Sees Isolated Incident and Strong Safety RecordFebruary 16, 2024 | msn.comInventiva halt recruitment for Phase III NASH trial following adverse eventFebruary 16, 2024 | marketwatch.comInventiva Stock Falls 20% After Pausing Screening, Randomization in Trial Due to Adverse EventFebruary 15, 2024 | finanznachrichten.deINVENTIVA: Inventiva reports preliminary 2023 fiscal year financial Information and provides an update on its clinical trial NATiV3See More Headlines Receive IVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inventiva and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IVA CUSIPN/A CIK1756594 Webwww.inventivapharma.com Phone33-3-80-44-75-00FaxN/AEmployees120Year Founded2011Price Target and Rating Average Stock Price Target$17.00 High Stock Price Target$25.00 Low Stock Price Target$11.00 Potential Upside/Downside+416.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.96 Quick Ratio0.95 Sales & Book Value Annual Sales$18.91 million Price / Sales9.13 Cash FlowN/A Price / Cash FlowN/A Book Value($0.67) per share Price / Book-4.91Miscellaneous Outstanding Shares52,480,000Free Float35,684,000Market Cap$172.66 million OptionableNot Optionable Beta0.90 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Pierre Broqua Ph.D. (Age 62)Co-Founder, Chief Scientific Officer, Deputy CEO & Director Comp: $439.12kMr. Frederic Cren (Age 58)Co-Founder, CEO & Chairman Comp: $535.77kMr. Jean Volatier (Age 59)Deputy GM & CFO Ms. Alice Roudot-Ketelers Pharm.D. (Age 53)Chief Operating Officer Mr. Eric Duranson L.L.M. (Age 50)General Counsel Ms. Nathalie Harroy (Age 57)Head of Human Resources Dr. Michael Cooreman (Age 66)Chief Medical Officer Ms. Pascaline Clerc Ph.D. (Age 44)Executive Vice President of Strategy & Corporate Affairs More ExecutivesKey CompetitorsAdicet BioNASDAQ:ACETTelomir PharmaceuticalsNASDAQ:TELOSkye BioscienceNASDAQ:SKYEGreenwich LifeSciencesNASDAQ:GLSIGossamer BioNASDAQ:GOSSView All Competitors IVA Stock Analysis - Frequently Asked Questions Should I buy or sell Inventiva stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inventiva in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IVA shares. View IVA analyst ratings or view top-rated stocks. What is Inventiva's stock price target for 2024? 8 equities research analysts have issued 1-year target prices for Inventiva's stock. Their IVA share price targets range from $11.00 to $25.00. On average, they expect the company's share price to reach $17.00 in the next year. This suggests a possible upside of 415.2% from the stock's current price. View analysts price targets for IVA or view top-rated stocks among Wall Street analysts. How have IVA shares performed in 2024? Inventiva's stock was trading at $4.52 at the start of the year. Since then, IVA stock has decreased by 27.0% and is now trading at $3.30. View the best growth stocks for 2024 here. Are investors shorting Inventiva? Inventiva saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 57,600 shares, a decline of 52.7% from the March 15th total of 121,900 shares. Based on an average daily volume of 39,400 shares, the days-to-cover ratio is currently 1.5 days. View Inventiva's Short Interest. When did Inventiva IPO? Inventiva (IVA) raised $103 million in an IPO on Friday, July 10th 2020. The company issued 7,500,000 shares at a price of $13.68 per share. Jefferies, Stifel and Guggenheim Securities acted as the underwriters for the IPO and H.C. Wainwright, Roth Capital Partners and KBC Securities were co-managers. How do I buy shares of Inventiva? Shares of IVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IVA) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inventiva S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
